Biotech Values

[jb_118]

"This again points to mistake TRIL made by declaring MTD with 1st sign of DLT, rushing to expansion cohorts before adequate dosing work by exploring alternative dosing schedules of priming, frequency etc to increase dose. "

Exactly my thought when I saw the FTSV dosing. This mistake has potentially cost TRIL dearly in time and resources. Nothing like a small company on a tight budget squander their clinical lead chasing indications with the wrong dose. They've tried to back into trying higher doses after a loading dose in some more recent work, but I'm still not convinced they've adequately explored the optimal dosing regime.